Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $560
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst David Phung has maintained an Overweight rating on Eli Lilly (NYSE:LLY) and raised the price target from $551 to $560.
July 21, 2023 | 10:53 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's price target has been raised from $551 to $560 by Morgan Stanley, which maintains an Overweight rating on the stock.
The raised price target and maintained Overweight rating by Morgan Stanley indicates a positive outlook for Eli Lilly. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100